Abstract
A number of cancer vaccine and gene therapy approaches are being evaluated in patients with lung cancer. Cancer vaccine strategies include GM-CSF gene-modified cancer cells, liposomal MUC1 peptide, anti-idiotype antibody targeting GD3, Mage-3 peptide, and mutant p53 pulsed dendritic cells among others. Preliminary human trials have demonstrated immune responses as well as tumor regression in late stage disease. The largest human gene therapy experience in lung cancer is with intratumoral gene replacement therapy, predominantly with p53, but such approaches are limited to locoregional disease control. Earlier stage gene therapy programs targeting the immune system or tumor vasculature hold promise as systemic therapies for treatment of advanced, disseminated disease.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / pharmacology
-
Cancer Vaccines*
-
Clinical Trials as Topic
-
Ether-A-Go-Go Potassium Channels
-
Genes, Transgenic, Suicide
-
Genes, p53*
-
Genetic Therapy*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics*
-
Membrane Proteins / genetics
-
Membrane Proteins / pharmacology
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / pharmacology
-
Nerve Tissue Proteins / genetics
-
Nerve Tissue Proteins / pharmacology
-
Potassium Channels / genetics
-
Potassium Channels / pharmacology
-
Potassium Channels, Voltage-Gated*
Substances
-
Angiogenesis Inhibitors
-
Antigens, Neoplasm
-
Cancer Vaccines
-
Ether-A-Go-Go Potassium Channels
-
KCNH4 protein, human
-
MAGEA3 protein, human
-
Membrane Proteins
-
Neoplasm Proteins
-
Nerve Tissue Proteins
-
Potassium Channels
-
Potassium Channels, Voltage-Gated